دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 2
Jeffrey R. Curtis,Sindhu R. Johnson,Donald D. Anthony,Reuben J. Arasaratnam,Lindsey R. Baden,Anne R. Bass,Cassandra Calabrese,Ellen M. Gravallese,Rafael Harpaz,Andrew Kroger,Rebecca E. Sadun,Amy S. Turner,Eleanor Anderson Williams,Ted R. Mikuls
doi : 10.1002/art.41877
Volume 73, Issue 8 p. e30-e45
To provide guidance to rheumatology providers on the use of coronavirus disease 2019 (COVID-19) vaccines for patients with rheumatic and musculoskeletal diseases (RMDs).
American College of Rheumatology Guidance for the Management of Pediatric Rheumatic Disease During the COVID-19 Pandemic: Version 2
Dawn M. Wahezi,Mindy S. Lo,Tamar B. Rubinstein,Sarah Ringold,Stacy P. Ardoin,Kevin J. Downes,Karla B. Jones,Ronald M. Laxer,Rebecca Pellet Madan,Amy S. Mudano,Amy S. Turner,David R. Karp,Jay J. Mehta
doi : 10.1002/art.41772
Volume 73, Issue 8 p. e46-e59
To provide clinical guidance to rheumatology providers who treat children with pediatric rheumatic disease (PRD) in the context of the coronavirus disease 2019 (COVID-19) pandemic.
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis
Mehrdad Maz,Sharon A. Chung,Andy Abril,Carol A. Langford,Mark Gorelik,Gordon Guyatt,Amy M. Archer,Doyt L. Conn,Kathy A. Full,Peter C. Grayson,Maria F. Ibarra,Lisa F. Imundo,Susan Kim,Peter A. Merkel,Rennie L. Rhee,Philip Seo,John H. Stone,Sangeeta Sule,Robert P. Sundel,Omar I. Vitobaldi,Ann Warner,Kevin Byram,Anisha B. Dua,Nedaa Husainat,Karen E. James,Mohamad A. Kalot,Yih Chang Lin,Jason M. Springer,Marat Turgunbaev,Alexandra Villa-Forte,Amy S. Turner,Reem A. Mustafa
doi : 10.1002/art.41774
Volume 73, Issue 8 p. 1349-1365
To provide evidence-based recommendations and expert guidance for the management of giant cell arteritis (GCA) and Takayasu arteritis (TAK) as exemplars of large vessel vasculitis.
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Sharon A. Chung,Carol A. Langford,Mehrdad Maz,Andy Abril,Mark Gorelik,Gordon Guyatt,Amy M. Archer,Doyt L. Conn,Kathy A. Full,Peter C. Grayson,Maria F. Ibarra,Lisa F. Imundo,Susan Kim,Peter A. Merkel,Rennie L. Rhee,Philip Seo,John H. Stone,Sangeeta Sule,Robert P. Sundel,Omar I. Vitobaldi,Ann Warner,Kevin Byram,Anisha B. Dua,Nedaa Husainat,Karen E. James,Mohamad A. Kalot,Yih Chang Lin,Jason M. Springer,Marat Turgunbaev,Alexandra Villa-Forte,Amy S. Turner,Reem A. Mustafa
doi : 10.1002/art.41773
Volume 73, Issue 8 p. 1366-1383
To provide evidence-based recommendations and expert guidance for the management of antineutrophil cytoplasmic antibody–associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA).
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa
Sharon A. Chung,Mark Gorelik,Carol A. Langford,Mehrdad Maz,Andy Abril,Gordon Guyatt,Amy M. Archer,Doyt L. Conn,Kathy A. Full,Peter C. Grayson,Maria F. Ibarra,Lisa F. Imundo,Susan Kim,Peter A. Merkel,Rennie L. Rhee,Philip Seo,John H. Stone,Sangeeta Sule,Robert P. Sundel,Omar I. Vitobaldi,Ann Warner,Kevin Byram,Anisha B. Dua,Nedaa Husainat,Karen E. James,Mohamad Kalot,Yih Chang Lin,Jason M. Springer,Marat Turgunbaev,Alexandra Villa-Forte,Amy S. Turner,Reem A. Mustafa
doi : 10.1002/art.41776
Volume 73, Issue 8 p. 1384-1393
To provide evidence-based recommendations and expert guidance for the management of systemic polyarteritis nodosa (PAN).
Expert Perspective: Management of Refractory Inflammatory Myopathy
Ingrid E. Lundberg
doi : 10.1002/art.41762
Volume 73, Issue 8 p. 1394-1407
The idiopathic inflammatory myopathies (IIMs) are chronic disorders characterized by inflammation in skeletal muscle but also in other organs such as the skin, lungs, joints, gastrointestinal tract, and heart. The effect of immunosuppressive treatment varies between individual patients and between organ manifestations within the same individual. Many patients respond poorly to first-line treatment with glucocorticoids and other immunosuppressive agents such as methotrexate or azathioprine, with symptoms persisting in the muscles, skin, and lungs, leading to refractory disease. Management of refractory IIM is a clinical challenge, and a systematic approach is proposed to better understand the lack of treatment response, in order to guide disease management. The first step in the management of refractory IIM is to recognize whether remaining symptoms are caused by persistent inflammation in the affected tissue or whether the symptoms may be attributable to damage preceding inflammation. Thus, a second diagnostic examination is recommended. Second, in particular for patients with remaining muscle weakness, it is important to ascertain whether the diagnosis of myositis is correct or whether another underlying muscle disorder could explain the symptoms. Third, with confirmation of remaining inflammation in the tissues, a strategy to change treatment needs to be undertaken. Few controlled trials are available to guide our treatment strategies. Furthermore, different subgroups of patients may benefit from different therapies, and different organ manifestations may respond to different therapies. In this context, subgrouping of patients with IIM based on autoantibody profile may be helpful, as there are emerging data from open studies and case series to support the notion of a varying treatment response in different autoantibody-defined subgroups of IIM patients.
Urate Lowering for Blood Pressure Control in Adults: Another Nail in the Coffin?
Edward Roddy,Nicola Dalbeth
doi : 10.1002/art.41751
Volume 73, Issue 8 p. 1408-1411
Epicardial Adipose Tissue Volume As a Marker of Subclinical Coronary Atherosclerosis in Rheumatoid Arthritis
George A. Karpouzas,Panteha Rezaeian,Sarah R. Ormseth,Ivana Hollan,Matthew J. Budoff
doi : 10.1002/art.41693
Volume 73, Issue 8 p. 1412-1420
To assess epicardial adipose tissue volume (EATV) and its link to coronary atherosclerosis and plaque morphology in patients with rheumatoid arthritis (RA) and in age- and sex-matched controls.
Outcomes of a Mobile App to Monitor Patient-Reported Outcomes in Rheumatoid Arthritis: A Randomized Controlled Trial
Yvonne C. Lee,Fengxin Lu,Joshua Colls,Dee Luo,Penny Wang,Dorothy D. Dunlop,Lutfiyya N. Muhammad,Jing Song,Kaleb Michaud,Daniel H. Solomon
doi : 10.1002/art.41686
Volume 73, Issue 8 p. 1421-1429
To examine the effects of a smartphone application (app) to monitor longitudinal electronic patient-reported outcomes (ePROs) on patient satisfaction and disease activity in patients with rheumatoid arthritis (RA).
Protective Role of Collectin 11 in a Mouse Model of Rheumatoid Arthritis
Na Wang,Weiju Wu,Cui Qiang,Ning Ma,Kunyi Wu,Dan Liu,Jia-Xing Wang,Xiao Yang,Li Xue,Teng-Yue Diao,Jia-Yu Liu,Ang Li,Baojun Zhang,Zong-Fang Li,Conrad A. Farrar,Nirmal K. Banda,Rafael Bayarri-Olmos,Peter Garred,Wuding Zhou,Ke Li
doi : 10.1002/art.41696
Volume 73, Issue 8 p. 1430-1440
Collectin 11 (CL-11) is a soluble C-type lectin, a mediator of innate immunity. Its role in autoimmune disorders is unknown. We undertook this study to determine the role of CL-11 in a mouse model of rheumatoid arthritis (RA).
Involvement of Transient Receptor Potential Vanilloid Channel 2 in the Induction of Lubricin and Suppression of Ectopic Endochondral Ossification in Mouse Articular Cartilage
Hideki Nakamoto,Yuki Katanosaka,Ryota Chijimatsu,Daisuke Mori,Fengjun Xuan,Fumiko Yano,Yasunori Omata,Yuji Maenohara,Yasutaka Murahashi,Kohei Kawaguchi,Ryota Yamagami,Hiroshi Inui,Shuji Taketomi,Yuki Taniguchi,Motoi Kanagawa,Keiji Naruse,Sakae Tanaka,Taku Saito
doi : 10.1002/art.41684
Volume 73, Issue 8 p. 1441-1450
Transient receptor potential vanilloid channel 2 (TRPV2) is a Ca2+-permeable channel and plays a role in mediating intracellular Ca2+ current via mechanical stimuli. This study was undertaken to examine the expression and role of TRPV2 in adult articular cartilage and the development of osteoarthritis (OA).
Lipopolysaccharide Binding Protein and CD14, Cofactors of Toll-like Receptors, Are Essential for Low-Grade Inflammation–Induced Exacerbation of Cartilage Damage in Mouse Models of Posttraumatic Osteoarthritis
Yoonkyung Won,Jeong-In Yang,Seulki Park,Jang-Soo Chun
doi : 10.1002/art.41679
Volume 73, Issue 8 p. 1451-1460
Osteoarthritis (OA) is initiated by pathogenic factors produced by multiple stimuli, including mechanical stress, metabolic stress, and/or inflammaging. This study was undertaken to identify novel low-grade inflammation–associated pathogenic mediators of OA.
Molecular Signatures of Kidney Antibody–Secreting Cells in Lupus Patients With Active Nephritis Upon Immunosuppressive Therapy
Etienne Crickx,Farah Tamirou,Tessa Huscenot,Nathalie Costedoat-Chalumeau,Marion Rabant,Alexandre Karras,Ailsa Robbins,Tatiana Fadeev,Véronique Le Guern,Philippe Remy,Aurélie Hummel,Selda Aydin,Bernard Lauwerys,Jean-Claude Weill,Claude-Agnès Reynaud,Frédéric Houssiau,Matthieu Mahévas
doi : 10.1002/art.41703
Volume 73, Issue 8 p. 1461-1466
This study was undertaken to characterize kidney and urine antibody-secreting cells (ASCs) from patients with active lupus nephritis, before and after induction therapy.
Aim2 Couples With Ube2i for Sumoylation-Mediated Repression of Interferon Signatures in Systemic Lupus Erythematosus
Ailing Lu,Shuxian Wu,Junling Niu,Mengmeng Cui,Mengdan Chen,William L. Clapp,Betsy J. Barnes,Guangxun Meng
doi : 10.1002/art.41677
Volume 73, Issue 8 p. 1467-1477
Systemic lupus erythematosus (SLE) involves kidney damage, and the inflammasome-caspase-1 axis has been demonstrated to promote renal pathogenesis. The present study was designed to explore the function of the Absent in Melanoma 2 (Aim2) protein in SLE.
Camptothecin and Topotecan, Inhibitors of Transcription Factor Fli-1 and Topoisomerase, Markedly Ameliorate Lupus Nephritis in (NZB × NZW)F1 Mice and Reduce the Production of Inflammatory Mediators in Human Renal Cells
Xuan Wang,Jim C. Oates,Kristi L. Helke,Gary S. Gilkeson,Xian K. Zhang
doi : 10.1002/art.41685
Volume 73, Issue 8 p. 1478-1488
To examine the therapeutic effects of camptothecin (CPT) and topotecan (TPT), inhibitors of transcription factor Fli-1 and topoisomerase, on lupus nephritis in (NZB × NZW)F1 (NZBWF1) mice, and to examine the effects of CPT and TPT on inflammatory mediators in human renal cells.
Retinoic Acid Receptor–Related Orphan Nuclear Receptor ?t Licenses the Differentiation and Function of a Unique Subset of Follicular Helper T Cells in Response to Immunogenic Self-DNA in Systemic Lupus Erythematosus
Zhenke Wen,Lin Xu,Wei Xu,Sidong Xiong
doi : 10.1002/art.41687
Volume 73, Issue 8 p. 1489-1500
Accumulating studies have identified self-DNA as driving IgG anti–double-stranded DNA (anti-dsDNA) in lupus, though the underpinning mechanisms of this process remain largely undefined. Here, we explored the activity of transcription factor retinoic acid receptor–related orphan nuclear receptor ?t (ROR?t) in the differentiation and function of self-DNA–specific follicular helper T (Tfh) cells in lupus.
Genome-Wide Reduction in Chromatin Accessibility and Unique Transcription Factor Footprints in Endothelial Cells and Fibroblasts in Scleroderma Skin
Pei-Suen Tsou,Pamela J. Palisoc,Mustafa Ali,Dinesh Khanna,Amr H. Sawalha
doi : 10.1002/art.41694
Volume 73, Issue 8 p. 1501-1513
Systemic sclerosis (SSc) is characterized by widespread fibrosis and vascular complications. This study was undertaken to examine the chromatin landscape and transcription factor footprints in SSc, using an assay for genome-wide chromatin accessibility.
Effect of Serum Urate Lowering With Allopurinol on Blood Pressure in Young Adults: A Randomized, Controlled, Crossover Trial
Angelo L. Gaffo,David A. Calhoun,Elizabeth J. Rahn,Suzanne Oparil,Peng Li,Tanja Dudenbostel,Daniel I. Feig,David T. Redden,Paul Muntner,Phillip J. Foster,Stephanie R. Biggers-Clark,Amy Mudano,Sebastian E. Sattui,Michael B. Saddekni,S. Louis Bridges Jr.,Kenneth G. Saag
doi : 10.1002/art.41749
Volume 73, Issue 8 p. 1514-1522
To determine whether serum urate reduction with allopurinol lowers blood pressure (BP) in young adults and the mechanisms mediating this hypothesized effect.
Reducing Immunogenicity of Pegloticase With Concomitant Use of Mycophenolate Mofetil in Patients With Refractory Gout: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial
Puja P. Khanna,Dinesh Khanna,Gary Cutter,Jeff Foster,Joshua Melnick,Sara Jaafar,Stephanie Biggers,A. K. M. Fazlur Rahman,Hui-Chien Kuo,Michelle Feese,Alan Kivitz,Charles King,William Shergy,Jeff Kent,Paul M. Peloso,Maria I. Danila,Kenneth G. Saag
doi : 10.1002/art.41731
Volume 73, Issue 8 p. 1523-1532
Pegloticase is used for the treatment of severe gout, but its use is limited by immunogenicity. This study was undertaken to evaluate whether mycophenolate mofetil (MMF) prolongs the efficacy of pegloticase.
A Randomized, Phase II Study Evaluating the Efficacy and Safety of Anakinra in the Treatment of Gout Flares
Kenneth G. Saag,Puja P. Khanna,Robert T. Keenan,Sven Ohlman,Lisa Osterling Koskinen,Erik Sparve,Ann-Charlotte ?kerblad,Margareta Wikén,Alexander So,Michael H. Pillinger,Robert Terkeltaub
doi : 10.1002/art.41699
Volume 73, Issue 8 p. 1533-1542
To evaluate the efficacy and safety of anakinra compared to triamcinolone in the treatment of gout flares.
Acute Digital Necrosis Due to Interferon-?–Induced Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Yoshinori Taniguchi,Takahito Kimata,Shigeto Kobayashi
doi : 10.1002/art.41700
Volume 73, Issue 8 p. 1542-1542
Effects of the TNFRSF11B Mutation Associated With Calcium Pyrophosphate Deposition Disease in Osteoclastogenesis in a Murine Model
Elizabeth Mitton-Fitzgerald,Claudia M. Gohr,Charlene J. Williams,Amaryllis Ortiz,Gabriel Mbalaviele,Ann K. Rosenthal
doi : 10.1002/art.41678
Volume 73, Issue 8 p. 1543-1549
The gene TNFRSF11B encodes for osteoprotegerin (OPG) and was recently identified as the CCAL1 locus associated with familial calcium pyrophosphate deposition disease (CPDD). While the CCAL1 OPG mutation (OPG-XL) was originally believed to be a gain-of-function mutation, loss of OPG activity causes arthritis-associated osteolysis in mice, which is likely related to excess subchondral osteoclast formation and/or activity. The purpose of the present study was to further explore the effect of OPG-XL in osteoclastogenesis.
Bilateral Calf Hypertrophy With Increased Muscle Enzyme Levels
Juhi Dixit,Rasmi Ranjan Sahoo,Hardeep Singh Malhotra,Kiran Preet Malhotra,Anupam Wakhlu
doi : 10.1002/art.41707
Volume 73, Issue 8 p. 1549-1549
A Proinflammatory Cytokine Network Profile in Th1/Type 1 Effector B Cells Delineates a Common Group of Patients in Four Systemic Autoimmune Diseases
Quentin Simon,Alexis Grasseau,Marina Boudigou,Laëtitia Le Pottier,Eléonore Bettachioli,Divi Cornec,Bénédicte Rouvière,Christophe Jamin,Lucas Le Lann,PRECISESADS Clinical Consortium,PRECISESADS Flow Cytometry Study Group,Maria Orietta Borghi,Rocio Aguilar-Quesada,Yves Renaudineau,Marta E. Alarc?n-Riquelme,Jacques-Olivier Pers,Sophie Hillion
doi : 10.1002/art.41697
Volume 73, Issue 8 p. 1550-1561
The effector T cell and B cell cytokine networks have been implicated in the pathogenesis of systemic autoimmune diseases, but the association of these cytokine networks with the heterogeneity of clinical manifestations and immune profiles has not been carefully examined. This study was undertaken to examine whether cytokine profiles can delineate distinct groups of patients in 4 systemic autoimmune diseases (systemic lupus erythematosus, Sj?gren’s syndrome, rheumatoid arthritis, and systemic sclerosis).
COVID-19 Disease in Patients With Recurrent Pericarditis During Treatment With Anakinra: Comment on the Article by Navarro-Mill?n et al
Enrica Negro,Lucia Trotta,Massimo Pancrazi,Emanuele Bizzi,Martino Brenna,Vartan Mardigyan,Massimo Imazio,Antonio Brucato
doi : 10.1002/art.41702
Volume 73, Issue 8 p. 1562-1563
Significance of Antistriational Antibodies for Immune Checkpoint Inhibitor–Related Myositis: Comment on the Article by Aldrich et al
Shigeaki Suzuki
doi : 10.1002/art.41713
Volume 73, Issue 8 p. 1563-1564
Reply
Sudhakar Tummala,Xerxes Pundole,Jeffrey Aldrich,Maria E. Suarez-Almazor
doi : 10.1002/art.41714
Volume 73, Issue 8 p. 1564-1564
Myositis-Specific Autoantibodies as Relevant Adjusting Variables in Myositis Research: Comment on the Article by Hou et al
Iago Pinal-Fernandez,Andrew L. Mammen
doi : 10.1002/art.41705
Volume 73, Issue 8 p. 1564-1566
Reply
Cyrielle Hou,François J. Authier,Cyril Gitiaux
doi : 10.1002/art.41706
Volume 73, Issue 8 p. 1566-1567
Use of Precision Medicine to Guide Treatment of Patients With Rheumatoid Arthritis: Comment on the Article by Tao et al
Stanley B. Cohen,Theodore Mellors,Martin J. Bergman
doi : 10.1002/art.41712
Volume 73, Issue 8 p. 1567-1569
Reply
Weiyang Tao,Timothy R. D. J. Radstake,Aridaman Pandit
doi : 10.1002/art.41711
Volume 73, Issue 8 p. 1569-1570
Adverse Events of Special Interest Incorrectly Referred to As Serious Adverse Events of Special Interest in the Article by Chatham et al (Arthritis Rheumatol, May 2021)
doi : 10.1002/art.41903
Volume 73, Issue 8 p. 1570-1570
